Recombinant and natural human interferons: Analysis of the incidence and clinical impact of neutralizing antibodies

Journal of Interferon and Cytokine Research

Volumn 32, Issue 3, 2012, Pages 95-102

  Strayer, David R ^a   Carter, William A ^a  

^a HEMISPHERX BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHAN1 INTERFERON; ALPHAN3 INTERFERON; BETA1A INTERFERON; EGIFERONE; HUMAN INTERFERON; INTERFERON BETA SERINE; MULTIFERON; NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERFERON; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIBODY RESPONSE; ANTIBODY TITER; CARCINOID; CHRONIC MYELOID LEUKEMIA; CROSSOVER PROCEDURE; CRYOGLOBULINEMIA; DOSE RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HAIRY CELL LEUKEMIA; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOTHERAPY; INJECTION; KIDNEY CARCINOMA; LEUKEMIA; META ANALYSIS; MULTIPLE SCLEROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RELAPSE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; REVIEW; SEROLOGY; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS HEPATITIS; VISUAL ACUITY;

ANTIBODIES, NEUTRALIZING; CROSS REACTIONS; HUMANS; INCIDENCE; INTERFERON TYPE I; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84857853991     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2011.0069     Document Type: Review

References (26)

1. Antonelli G, Giannelli G, Currenti M, Simeoni E, Del Vecchio S, Maggi F, Pistello M, Roffi L, Pastore G, Chemello L, Dianzani F. 1996. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-a2 therapy. Clin Exp Immunol 104:384-387.
2. Antonelli G, Simeoni E, Bagnato F, Pozzilli C, Turriziani O, Tesoro R, Di Marco P, Gasperini C, Fieschi C, Ferdinando D. 1999. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neur Sci 168:131-136.
3. Bonetti P, Diodati G, Drago C, Casarin, C, Scaccabarozzi S, Realdi G, Ruol A, Alberti A. 1994. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2a. J Hepatol 20:416-420.
4. Brand CM, Leadbeater L, Bellati G, Marotta F, Ideo O. 1993. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-a subtypes. J Interferon Res 13:121-125.
5. Casato M, Lagana B, Antonelli G, Dianzani F, Bonomo L. 1991. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 78(12):3142-3147.
6. IFNB Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. 1996. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b. Neurology 47:889-894.
7. Liao MJ, Axelrod HR, Kuchler M, Yip YK, Kirkbright E, Testa D. 1992. Absence of neutralizing antibodies to interferon in condyloma acuminata and cancer patients treated with natural human leukocyte interferon. JID 165:757-760.
8. Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, Angarano G, Dianzani F, Pastore G. 1993. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 13:146-150.
9. Oberg K, Alm G. 1997. The Incidence and clinical significance of antibodies to interferon-a in patients with solid tumors. Biotherapy 10:1-5.
10. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B. 2002. Randomized, comparative study of interferon b-1a treatment regimens in MS: The EVIDENCE trial. Neurology 59:1496-1506.
11. Porres JC, Carreno V, Ruiz M, Marron JA, Bartolome J. 1989. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatology 8:351-357.
12. PRISMS Study Group and University of British Columbia MS/ MRI Analysis Group. 2001. PRISMS-4: Long-term efficacy of interferon-b-1a in relapsing MS. Neurology 56:1628-1636.
13. Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU. 1985. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 3: 1522-1528.
14. Roffi L, Mels GC, Antonelli G, Bellati G, Panizzuti F, Piperno A, Pozzi M, Ravizza D, Angeli G, Dianzani F and Mancia G. 1995. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: Prevalence, etiology, and management. Hepatology 21:645-649.
15. Ross C, Engler CB, Sander B, Bendtzen K. 2002. IFN-a antibodies in patients with age-related macular degeneration treated with recombinant human IFN-a2a. J Interferon Cytokine Res 22:421-426.
16. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, and others. 1998. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50:1266-1272.
17. Russo D, Candoni A, Zuffa E, Minisini R, Silvestri F, Fanin R, Zaja F, Martinelli G, Tura S, Botta G, Baccarani, M. 1996. Neutralizing anti-interferon-a antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (a2a) and lymphoblastoid interferon-a. Br J Haematol 94:300-305.
18. Santantonio T, Milella M, Antonelli G, Scagnolari C. 2006. Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon. J Hepatol 45:758-761.
19. Sherman K, Bacon B, Feinman V, Jeffers J, Alferon Cooperative Study Group. 1999. Efficacy of interferon alfa-n3 vs. recombinant interferon in the treatment of chronic hepatitis C virus infection: A multicenter, randomized trial. Poster at the American College of Gastroenterology Annual Meeting.
20. Skillman DR, Malone JL, Decker CF, Wagner KF, Mapou RL, Liao MJ, Testa D, Meltzer MS. 1996. Phase I trial of interferon alfa-n3 in early-stage human immunodeficiency virus type 1 disease: Evidence for drug safety, tolerance, and antiviral activity. JID 173:1107-1114.
21. Steis RG, Longo DL. 1994. Clinical relevance of recombinant interferon-a2a antibodies in patients with hairy cell leukemia. J Interferon Res 14:207-209.
22. Tefferi A, Grendahl DC. 1996. Natural leukocyte interferon-a therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-a. Am J Hematol 52:231-233.
23. van der Eijk AA, Vrolijk JM, Haagmans BL. 2006. Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. NEJM 354:1323-1324.
24. von Wussow P, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H. 1987. Clinical significance of anti-IFN-a antibody titres during interferon therapy. Lancet 12:635-636.
25. von Wussow P, Pralle H, Hochkeppel HK, Jakschies D, Sonnen S, Schmidt H, Muller-Rosenau D, Franke M, Haferlach T, Zwingers T, Rapp U, Deicher H. 1991. Effective natural interferon-a therapy in recombinant interferon-a-resistant patients with hairy cell leukemia. Blood 78:38-43.
26. Zhao X-X, Hua J, Smith T, Ferencz-Biro K, Liao J-J, Rashidbaigi A. 1997. Interferon-a neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-an3. Hum Antibodies 8(3):129-136.